查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026836

2034年尿道感染市場預測－按產品、治療方法、檢測類型、適應症、通路、最終用戶和地區分類的全球分析

Urinary Tract Infection Market Forecasts to 2034 - Global Analysis By Product, Treatment Type, Test Type, Indication, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球尿道感染市場規模將達到 82 億美元，並在預測期內以 7.67% 的複合年成長率成長，到 2034 年將達到 149 億美元。

尿道感染 ) 檢測是指透過尿液檢查來發現和管理多種疾病，包括尿道感染、尿道感染疾病和糖尿病。泌尿道感染主要由細菌進入尿道並在泌尿道內繁殖引起，是一種常見疾病。醫療保健市場透過提供專門針對尿道感染的診斷工具、抗生素和治療方案，為醫療保健產業做出貢獻。

根據美國家庭醫師學會 (AAFP) 的 Leonardo Ferreira 於 2020 年 3 月發布的報告，腎結石是一種常見疾病，年發生率為每千人 8 例。同一資訊來源指出，大約 13% 的男性和 7% 的女性在一生中的某個階段可能會患上腎結石，而美國男性閉尿症的總體發病率在每年每千人 4.5 至 6.8 例之間。

尿道感染發生率增加

尿道感染（UTI）的日益流行，尤其是在女性、老年人和免疫力較弱的人群中，推動了對診斷和治療方法的需求。人口老化、人們對泌尿道感染的認知以及對早期發現和及時治療日益重視，都是推動泌尿道感染市場成長的因素。此外，這些市場促進因素也凸顯了對新型診斷方法、抗生素和預防措施的需求，從而刺激了對泌尿道感染新產品和治療方法研發的投資和研究。

抗生素抗藥性增強

抗生素的過度使用和濫用導致了抗藥性細菌的出現，使得尿道感染（ UTI）的有效治療日益困難。這種抗藥性限制了現有抗生素的療效，並使標準治療方案複雜化，因此亟需新的治療方案。為了應對尿道感染治療中的抗生素抗藥性問題，研發工作必須集中在尋找新藥和替代治療方法。

引進新的診斷技術

照護現場診斷和快速分子檢測是先進的診斷工具，能夠更快、更準確地識別尿道感染(UTI)。這有助於合理使用抗生素，緩解日益嚴重的抗生素抗藥性問題，並透過及時治療提高患者照護品質。投資於尖端尿道感染感染診斷解決方案的公司將受益於市場對精準高效診斷技術日益成長的需求，這將改善整體醫療保健效果，並減輕尿道感染治療的經濟負擔。

缺乏意識

泌尿道感染（UTI）是常見的泌尿系統細菌感染疾病，由於大眾缺乏對其原因、症狀和預防的了解，常常被忽視。這種認知不足阻礙了早期診斷和適當的醫療干預，導致併發症和醫療成本增加。此外，對衛生習慣的誤解和資訊不足也是泌尿道感染傳播的因素之一。這種認知不足不僅影響個人健康，也加重了醫療體系的負擔。

新冠疫情的感染疾病：

過度關注控制和遏制病毒傳播，導致醫療資源、注意力和資金從其他疾病（包括泌尿道感染）的治療中轉移。封鎖措施、醫療服務受限以及患者對就醫的擔憂，都造成了診斷和治療的延誤，從而導致尿路感染病情加重。此外，為治療新冠病毒相關細菌感染疾病而大量使用抗生素，加劇了抗生素抗藥性，這可能會降低常規泌尿道感染治療的療效。供應鏈中斷也影響了泌尿道感染治療和診斷的供應。

在預測期內，抗生素領域預計將佔據最大佔有率。

在預測期內，抗生素預計將佔據最大市場佔有率。在尿道感染市場的抗生素細分領域，多種藥物被用於治療泌尿道細菌感染疾病。 BETA-內醯胺類抗生素（如阿莫西林）和Fluoroquinolones抗生素（如Ciprofloxacin）是治療尿道感染的常用抗生素。此外，持續的研發工作旨在減少副作用、降低抗藥性並提高這些抗生素的療效。

在預測期內，臨床檢查室領域預計將呈現最高的複合年成長率。

預計尿道感染市場中的臨床檢查室細分領域將實現盈利成長。臨床檢查室在透過分析尿液檢體（包括評估細菌存在和確定抗生素敏感性）來識別和確診尿道感染(UTI) 方面發揮著至關重要的作用。這些檢查室利用先進的技術和檢測方法，確保快速且準確地獲得結果，從而實現及時的醫療干預。此外，這些檢查室引入自動化和分子診斷技術，進一步提高了尿道感染診斷的效率和準確性。

市佔率最大的地區：

亞太地區尿道感染（ UTI）市場正顯著擴張，這主要受醫療保健成本上升、醫療基礎設施改善以及人們對尿道感染的認知提高等因素的推動，從而刺激了對診斷和治療方案的需求。生活方式的改變和人口老化也是導致尿道感染發生率上升的原因之一。此外，政府的支持措施以及製藥和醫療保健公司的發展也進一步促進了該地區市場的擴張。

複合年成長率最高的地區：

在歐洲，由於老年人口成長和意識提升，尿道感染市場正在顯著擴張。糖尿病和尿失禁等風險因素的日益普遍也推動了歐洲市場的成長要素。此外，各國政府開展的旨在提高公眾對泌尿系統健康問題認知並鼓勵預防措施的宣傳活動，在推動歐盟市場成長方面發揮著至關重要的作用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球尿道感染市場：依產品分類

  • Azole藥物和雙性殺黴素B
  • 頭孢菌素
  • 硝基呋喃類藥物
  • 青黴素和組合藥物
  • 奎諾酮藥物
  • 其他產品

第6章 全球尿道感染市場：依治療方法

  • 抗生素
  • 止痛藥
  • 解痙藥
  • 其他治療方法

第7章 全球尿道感染市場：依檢測類型分類

  • 顯微鏡檢查
  • 生物化學檢驗
  • 流式細胞技術
  • 其他測試類型

第8章：全球尿道感染市場：依適應症分類

  • 複雜性尿道感染
  • 神經源性膀胱感染疾病
  • 復發性複雜性尿道感染
  • 單純性尿道感染
  • 其他改編

第9章：全球尿道感染市場：依通路分類

  • 藥局
  • 婦科及泌尿系統診所
  • 零售藥房
  • 其他分銷管道

第10章 全球尿道感染市場：依最終用戶分類

  • 醫院
  • 臨床檢查室
  • 家庭醫療保健
  • 其他最終用戶

第11章 全球尿道感染市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Allergan Plc
  • Arkray, Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Elektronika Kft.
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Mindray Medical International Limited
  • Novartis Ag
  • Pfizer Inc
  • Roche Diagnostics
  • Sanofi SA
  • Siemens Healthcare
  • Sysmex Corporation
  • Urit Medical Electronic Group Co., Ltd.
Product Code: SMRC24720

According to Stratistics MRC, the Global Urinary Tract Infection Market is accounted for $8.2 billion in 2026 and is expected to reach $14.9 billion by 2034 growing at a CAGR of 7.67% during the forecast period. Urinary Tract Infections is a test of urine to detect and manage a wide range of disorders, such as urinary tract infections, kidney disease and diabetes. UTIs, caused primarily by bacteria entering the urethra and multiplying in the urinary tract, are common medical conditions. It serves the healthcare sector by providing diagnostic tools, antibiotics, and therapeutics tailored for UTI management.

According to the American Academy of Family Physicians (AAFP), in March 2020, by Leonardo Ferreira, kidney stones were a common ailment, with an annual incidence of eight instances per 1,000 persons. As per the same source, around 13% of men and 7% of women may develop a kidney stone during their lifetime, and the total incidence of urinary retention in the US is 4.5 to 6.8 per 1,000 men per year.

Market Dynamics:

Driver:

Increasing prevalence of urinary tract infections

The increasing prevalence of urinary tract infections (UTIs), especially in women, the elderly, and people with weakened immune systems, is driving up demand for diagnostic and treatment options. The aging population, increased knowledge of UTIs, and a growing emphasis on early detection and timely treatment are some of the factors driving the UTI market's growth. Furthermore, the need for novel diagnostics, antibiotics, and preventive measures is highlighted by this market driver, which encourages investment and research in the creation of fresh goods and remedies for UTIs.

Restraint:

Rising instances of antibiotic resistance

Effective treatment of urinary tract infections is becoming more difficult due to the emergence of resistant bacterial strains caused by the overuse and misuse of antibiotics. The need for new therapeutic solutions arises from the fact that this resistance limits the effectiveness of current antibiotics and complicates standard treatment regimens. In order to combat antibiotic resistance in UTI management, research and development efforts must be concentrated in order to find new medications and alternative treatment modalities.

Opportunity:

Adoption of novel diagnostic technologies

Point-of-care diagnostics and rapid molecular testing are instances of advanced diagnostic tools that can help identify UTIs more quickly and accurately. This helps to effectively use antibiotics, addressing the growing concern of antibiotic resistance, and improves patient care by enabling timely treatment. Businesses that invest in cutting-edge UTI diagnostic solutions will profit from the growing need for accurate and efficient diagnostic techniques, which will enhance overall healthcare outcomes and lessen the financial burden of UTI treatment.

Threat:

Lack of awareness

UTIs, common bacterial infections affecting the urinary system, often go undetected due to insufficient public knowledge about their causes, symptoms, and preventive measures. This dearth of awareness hampers early diagnosis and timely medical intervention, leading to complications and increased healthcare costs. However, misconceptions and inadequate information about hygiene practices contribute to the prevalence of UTIs. The lack of awareness not only affects individual health outcomes but also burdens healthcare systems.

Covid-19 Impact:

The overwhelming focus on managing and containing the virus has diverted healthcare resources, attention, and funding away from other medical conditions, including UTIs. Lockdowns, restricted healthcare access, and patient concerns about visiting medical facilities have led to delayed diagnoses and treatments, exacerbating the severity of UTIs. Moreover, the increased use of antibiotics to treat Covid-19-related bacterial infections has contributed to antibiotic resistance, potentially limiting the effectiveness of standard UTI treatments. Supply chain disruptions have also affected the availability of UTI medications and diagnostics.

The antibiotics segment is expected to be the largest during the forecast period

The antibiotics segment expected to have largest share over the anticipated period. A wide variety of medications are used to treat bacterial infections of the urinary tract in the Urinary Tract Infection market's antibiotics segment. Beta-lactam antibiotics, like amoxicillin, and fluoroquinolones, like ciprofloxacin, are frequently prescribed antibiotics for urinary tract infections. Additionally, the goals of ongoing research and development are to reduce side effects, minimize resistance, and improve the effectiveness of these antibiotics.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

Clinical laboratories segment in the urinary tract infection market is expected to have profitable growth. Clinical laboratories are pivotal in the identification and confirmation of UTIs through the analysis of urine samples, which includes assessing bacterial presence and determining antibiotic susceptibility. These laboratories utilize advanced technologies and testing methods to ensure accurate and timely results, facilitating prompt medical intervention. Moreover, the adoption of automation and molecular diagnostic techniques within these laboratories enhances the efficiency and precision of UTI diagnostics.

Region with largest share:

The Asia-Pacific Urinary Tract Infection market is expanding substantially due to the need for diagnostic and treatment solutions is being driven by rising healthcare costs, better healthcare infrastructure, and increased awareness of UTIs. The increased frequency of UTIs is also attributed to a changing lifestyle and an aging population. Additionally, favourable government initiatives and the growth of pharmaceutical and healthcare companies are driving the regional growth.

Region with highest CAGR:

The market for urinary tract infections is expanding substantially in Europe due to a growing geriatric population and rising public awareness. The market is growing due to risk factors like diabetes and urine incontinence are becoming more common, which is also driving growth in Europe. Additionally, government campaigns to raise awareness of urinary health issues and encourage preventative measures have been crucial in driving market growth in the European Union.

Key players in the market

Some of the key players in Urinary Tract Infection market include Abbott Laboratories , Acon Laboratories, Inc., Allergan Plc, Arkray, Inc., Astrazeneca Plc, Bayer Ag , Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Elektronika Kft., F. Hoffmann-La Roche Ltd, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co. Inc, Mindray Medical International Limited, Novartis Ag, Pfizer Inc, Roche Diagnostics, Sanofi S.A., Siemens Healthcare, Sysmex Corporation and Urit Medical Electronic Group Co., Ltd.

Key Developments:

In December 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The Agreement is based on a basic agreement on business collaboration in the field of immunoassay. Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

In December 2023, AstraZeneca Pharma India has entered into a Memorandum of Understanding (MoU) with Roche Diagnostics India to enhance diagnostics for breast cancer patients, particularly focusing on refining HER2 diagnostics with the latest advancements. This strategic alliance aligns with AstraZeneca's commitment to advancing patient-centric healthcare solutions and Roche Diagnostics' dedication to pioneering diagnostic innovation.

Products Covered:

  • Azoles and Amphotericin B
  • Cephalosporin
  • Nitrofurans
  • Penicillin and Combinations
  • Quinolones
  • Other Products

Treatment Types Covered:

  • Antibiotics
  • Analgesics
  • Antispasmodics
  • Other Treatment Types

Test Types Covered:

  • Microscopic Urinary Tract Infections
  • Biochemical Urinary Tract Infections
  • Flow Cytometric Urinary Tract Infections
  • Other Test Types

Indications Covered:

  • Complicated Urinary Tract Infection
  • Neurogenic Bladder Infections
  • Recurring Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection
  • Other Indications

Distribution Channels Covered:

  • Drug Stores
  • Gynaecology and Urology Clinics
  • Retail Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Clinical Laboratories
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urinary Tract Infection Market, By Product

  • 5.1 Introduction
  • 5.2 Azoles and Amphotericin B
  • 5.3 Cephalosporin
  • 5.4 Nitrofurans
  • 5.5 Penicillin and Combinations
  • 5.6 Quinolones
  • 5.7 Other Products

6 Global Urinary Tract Infection Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Antibiotics
  • 6.3 Analgesics
  • 6.4 Antispasmodics
  • 6.5 Other Treatment Types

7 Global Urinary Tract Infection Market, By Test Type

  • 7.1 Introduction
  • 7.2 Microscopic Urinary Tract Infections
  • 7.3 Biochemical Urinary Tract Infections
  • 7.4 Flow Cytometric Urinary Tract Infections
  • 7.5 Other Test Types

8 Global Urinary Tract Infection Market, By Indication

  • 8.1 Introduction
  • 8.2 Complicated Urinary Tract Infection
  • 8.3 Neurogenic Bladder Infections
  • 8.4 Recurring Complicated Urinary Tract Infection
  • 8.5 Uncomplicated Urinary Tract Infection
  • 8.6 Other Indications

9 Global Urinary Tract Infection Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Drug Stores
  • 9.3 Gynaecology and Urology Clinics
  • 9.4 Retail Pharmacies
  • 9.5 Other Distribution Channels

10 Global Urinary Tract Infection Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinical Laboratories
  • 10.4 Home Healthcare
  • 10.5 Other End Users

11 Global Urinary Tract Infection Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Acon Laboratories, Inc.
  • 13.3 Allergan Plc
  • 13.4 Arkray, Inc.
  • 13.5 Astrazeneca Plc
  • 13.6 Bayer Ag
  • 13.7 Beckman Coulter, Inc.
  • 13.8 Bio-Rad Laboratories, Inc.
  • 13.9 Elektronika Kft.
  • 13.10 F. Hoffmann-La Roche Ltd
  • 13.11 Glaxosmithkline Plc
  • 13.12 Johnson & Johnson
  • 13.13 Merck & Co. Inc
  • 13.14 Mindray Medical International Limited
  • 13.15 Novartis Ag
  • 13.16 Pfizer Inc
  • 13.17 Roche Diagnostics
  • 13.18 Sanofi S.A.
  • 13.19 Siemens Healthcare
  • 13.20 Sysmex Corporation
  • 13.21 Urit Medical Electronic Group Co., Ltd.

List of Tables

  • Table 1 Global Urinary Tract Infection Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Urinary Tract Infection Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Urinary Tract Infection Market Outlook, By Azoles and Amphotericin B (2023-2034) ($MN)
  • Table 4 Global Urinary Tract Infection Market Outlook, By Cephalosporin (2023-2034) ($MN)
  • Table 5 Global Urinary Tract Infection Market Outlook, By Nitrofurans (2023-2034) ($MN)
  • Table 6 Global Urinary Tract Infection Market Outlook, By Penicillin and Combinations (2023-2034) ($MN)
  • Table 7 Global Urinary Tract Infection Market Outlook, By Quinolones (2023-2034) ($MN)
  • Table 8 Global Urinary Tract Infection Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 9 Global Urinary Tract Infection Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 10 Global Urinary Tract Infection Market Outlook, By Antibiotics (2023-2034) ($MN)
  • Table 11 Global Urinary Tract Infection Market Outlook, By Analgesics (2023-2034) ($MN)
  • Table 12 Global Urinary Tract Infection Market Outlook, By Antispasmodics (2023-2034) ($MN)
  • Table 13 Global Urinary Tract Infection Market Outlook, By Other Treatment Types (2023-2034) ($MN)
  • Table 14 Global Urinary Tract Infection Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 15 Global Urinary Tract Infection Market Outlook, By Microscopic Urinary Tract Infections (2023-2034) ($MN)
  • Table 16 Global Urinary Tract Infection Market Outlook, By Biochemical Urinary Tract Infections (2023-2034) ($MN)
  • Table 17 Global Urinary Tract Infection Market Outlook, By Flow Cytometric Urinary Tract Infections (2023-2034) ($MN)
  • Table 18 Global Urinary Tract Infection Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 19 Global Urinary Tract Infection Market Outlook, By Indication (2023-2034) ($MN)
  • Table 20 Global Urinary Tract Infection Market Outlook, By Complicated Urinary Tract Infection (2023-2034) ($MN)
  • Table 21 Global Urinary Tract Infection Market Outlook, By Neurogenic Bladder Infections (2023-2034) ($MN)
  • Table 22 Global Urinary Tract Infection Market Outlook, By Recurring Complicated Urinary Tract Infection (2023-2034) ($MN)
  • Table 23 Global Urinary Tract Infection Market Outlook, By Uncomplicated Urinary Tract Infection (2023-2034) ($MN)
  • Table 24 Global Urinary Tract Infection Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 25 Global Urinary Tract Infection Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 26 Global Urinary Tract Infection Market Outlook, By Drug Stores (2023-2034) ($MN)
  • Table 27 Global Urinary Tract Infection Market Outlook, By Gynaecology and Urology Clinics (2023-2034) ($MN)
  • Table 28 Global Urinary Tract Infection Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 29 Global Urinary Tract Infection Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 30 Global Urinary Tract Infection Market Outlook, By End User (2023-2034) ($MN)
  • Table 31 Global Urinary Tract Infection Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 32 Global Urinary Tract Infection Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 33 Global Urinary Tract Infection Market Outlook, By Home Healthcare (2023-2034) ($MN)
  • Table 34 Global Urinary Tract Infection Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.